The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study

被引:6
|
作者
Lev-Ari, Shaked [1 ]
Serzan, Michael [2 ]
Wu, Tianmin [3 ]
Ip, Andrew [4 ,5 ,6 ]
Pascual, Lauren [4 ]
Sinclaire, Brittany [4 ]
Adams, Shari [5 ]
Marafelias, Michael [4 ]
Ayyagari, Lakshmi [4 ]
Gill, Sarvarinder K. [4 ]
Ma, Barbara [7 ]
Zaemes, Jacob P. [1 ]
Della Pia, Alexandra [5 ]
Alaoui, Adil [8 ]
Madhavan, Subha [8 ]
Belouali, Anas [8 ]
Pecora, Andrew [4 ,5 ,6 ]
Ahn, Jaeil [3 ]
Atkins, Michael B. [1 ]
Shah, Neil J. [7 ,9 ]
机构
[1] Georgetown Lombardi Comprehens Canc Ctr, Dept Oncol, Georgetown, WA USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20007 USA
[4] Hackensack Meridian Hlth, John Theurer Canc Ctr, Hackensack, NJ USA
[5] Hackensack Meridian Hlth, Dept Oncol, Hackensack, NJ USA
[6] Hackensack Meridian Sch Med, Nutley, NJ USA
[7] Weill Cornell Med Ctr, Dept Med, New York, NY USA
[8] Georgetown Univ, Innovat Ctr Biomed Informat, Washington, DC USA
[9] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
关键词
immune checkpoint inhibitors; immune-related adverse events; immunosuppressive agents; melanoma; nivolumab; pembrolizumab; steroids; ADVERSE EVENTS; NIVOLUMAB; IPILIMUMAB; SURVIVAL;
D O I
10.1002/cncr.34742
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundImmune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their impact on ICI efficacy is not well studied. The impact of the use of ISAs on ICI efficacy in patients with advanced melanoma was therefore investigated. MethodsThis is a real-world, multicenter, retrospective cohort study of patients with advanced melanoma who received ICIs (n = 370). Overall survival (OS) and time to treatment failure (TTF) from the time of ICI initiation were compared among patients in subgroups of interest by unadjusted and 12-week landmark sensitivity-adjusted analyses. The association of irAEs and their management with OS and TTF were evaluated using univariate and multivariable Cox proportional hazards regression models. ResultsOverall, irAEs of any grade and of grade >= 3 occurred in 57% and 23% of patients, respectively. Thirty-seven percent of patients received steroids, and 3% received other ISAs. Median OS was longest among patients receiving both (not reached [NR]), shorter among those receiving only systemic steroids (SSs) (84.2 months; 95% CI, 40.2 months to NR), and shortest among those who did not experience irAEs (10.3 months; 95% CI, 6-20.1 months) (p < .001). Longer OS was significantly associated with the occurrence of irAEs and the use of SSs with or without ISAs upon multivariable-adjusted analysis (p < .001). Similar results were noted with anti-programmed death 1 (PD-1) monotherapy and combination anti-PD-1 plus anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy, and with 12-week landmark sensitivity analysis (p = .01). ConclusionsThese findings in patients with melanoma who were treated with ICIs suggest that the use of SSs or ISAs for the management of irAEs is not associated with inferior disease outcomes, which supports the use of these agents when necessary.
引用
收藏
页码:1885 / 1894
页数:10
相关论文
共 50 条
  • [1] Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study
    Jin, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S851 - S852
  • [2] Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study
    Su, Ruopeng
    Chen, Zeyu
    Hong, Daoping
    Jiang, Shuai
    Yuan, Yichu
    Cai, Xingyun
    Hu, Hailong
    Fu, Changde
    Huang, Zhiyang
    Wang, Zhenyu
    Zheng, Bing
    Huang, Jian
    Wang, Zaoyu
    Bao, Yige
    Cai, Ming
    Guo, Jianming
    Chen, Minfeng
    Wei, Qiang
    Huang, Jiwei
    Xue, Wei
    CANCER MEDICINE, 2023, 12 (09): : 10587 - 10596
  • [3] The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
    Iinuma, Koji
    Yamada, Toyohiro
    Kameyama, Koji
    Taniguchi, Tomoki
    Kawada, Kei
    Ishida, Takashi
    Nagai, Shingo
    Enomoto, Torai
    Ueda, Shota
    Takagi, Kimiaki
    Kawase, Makoto
    Takeuchi, Shinichi
    Kawase, Kota
    Kato, Daiki
    Takai, Manabu
    Nakane, Keita
    Koie, Takuya
    CANCERS, 2023, 15 (03)
  • [4] Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study
    Lushan Xiao
    Yanxia Liao
    Jiaren Wang
    Qimei Li
    Hongbo Zhu
    Chang Hong
    Ruining Li
    Jingzhe He
    Hao Cui
    Hanzhi Dong
    Lin Zeng
    Li Liu
    Cancer Immunology, Immunotherapy, 2023, 72 : 2299 - 2308
  • [5] Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study
    Xiao, Lushan
    Liao, Yanxia
    Wang, Jiaren
    Li, Qimei
    Zhu, Hongbo
    Hong, Chang
    Li, Ruining
    He, Jingzhe
    Cui, Hao
    Dong, Hanzhi
    Zeng, Lin
    Liu, Li
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2299 - 2308
  • [6] Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).
    Nakamura, Yasuhiro
    Namikawa, Kenjiro
    Yoshino, Koji
    Yoshikawa, Shusuke
    Uchi, Hiroshi
    Goto, Katsunobu
    Nakamura, Yoshiyuki
    Fukushima, Satoshi
    Kiniwa, Yukiko
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Kawai, Toru
    Hatta, Naohito
    Funakoshi, Takeru
    Teramoto, Yukiko
    Otsuka, Atsushi
    Doi, Haruki
    Ogata, Dai
    Matsushita, Shigeto
    Yamazaki, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China
    Yang, Yang
    Tan, Lijie
    Hu, Jian
    Li, Yin
    Mao, Yousheng
    Tian, Ziqiang
    Zhang, Baihua
    Ma, Jianqun
    Li, Hecheng
    Chen, Chun
    Chen, Keneng
    Han, Yongtao
    Chen, Longqi
    Liu, Junfeng
    Yu, Bentong
    Yu, Zhentao
    Li, Zhigang
    DISEASES OF THE ESOPHAGUS, 2022, 35 (11)
  • [8] Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
    Bol, K. F.
    Ellebaek, E.
    Donia, M.
    Schmidt, H.
    Bastholt, L.
    Kiilgaard, J. F.
    Svane, I-M.
    ANNALS OF ONCOLOGY, 2019, 30 : 539 - 539
  • [9] Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
    Bol, Kalijn Fredrike
    Ellebaek, Eva
    Hoejberg, Lise
    Bagger, Mette Marie
    Larsen, Mathilde Skaarup
    Klausen, Tobias Wirenfeldt
    Kohler, Ulrich Heide
    Schmidt, Henrik
    Bastholt, Lars
    Kiilgaard, Jens Folke
    Donia, Marco
    Svane, Inge Marie
    CANCERS, 2019, 11 (10)
  • [10] Retreatment with immune checkpoint inhibitors (ICIs) for patients with advanced gastric cancer: A retrospective, real-world study.
    Jia, Yong-Xu
    Liu, Yihan
    Han, Hui-Qiong
    Gao, Ya-Ping
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 343 - 343